Journey

Free public records show Journey in 1 of the markets we cover. It is not a key player in our research.

Public data

Free public data on Journey

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

US drug approvals

6 approvals with a product on the US market

  • Emrosi NDA219015 · approved 1 Nov 2024
  • Zilxi NDA213690 · approved 28 May 2020
  • Amzeeq NDA212379 · approved 18 Oct 2019
  • Qbrexza NDA210361 · approved 28 Jun 2018
  • Exelderm NDA018737 · approved 28 Feb 1989

Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.

See them on openFDA (opens in a new tab)

Markets where public records show them

Markets we cover where free public records show Journey: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Healthcare Topics

The topics of the markets Journey is in.

All healthcare topics

Search all reports for Journey All companies